Crossmark

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Crossref DOI link: https://doi.org/10.1038/s41586-021-03431-4

Published Online: 2021-03-16

Published Print: 2021-05-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuan, Shuofeng

Yin, Xin https://orcid.org/0000-0003-2357-6718
Meng, Xiangzhi

Chan, Jasper Fuk-Woo https://orcid.org/0000-0001-6336-6657
Ye, Zi-Wei

Riva, Laura

Pache, Lars https://orcid.org/0000-0002-4193-1042
Chan, Chris Chun-Yiu

Lai, Pok-Man https://orcid.org/0000-0002-7967-8126
Chan, Chris Chung-Sing

Poon, Vincent Kwok-Man

Lee, Andrew Chak-Yiu https://orcid.org/0000-0002-8432-3282
Matsunaga, Naoko

Pu, Yuan https://orcid.org/0000-0002-7049-8452
Yuen, Chun-Kit

Cao, Jianli

Liang, Ronghui

Tang, Kaiming

Sheng, Li https://orcid.org/0000-0002-3139-8045
Du, Yushen https://orcid.org/0000-0002-8015-4207
Xu, Wan

Lau, Chit-Ying

Sit, Ko-Yung https://orcid.org/0000-0001-6289-663X
Au, Wing-Kuk https://orcid.org/0000-0002-6196-7317
Wang, Runming https://orcid.org/0000-0001-8525-5659
Zhang, Yu-Yuan

Tang, Yan-Dong

Clausen, Thomas Mandel

Pihl, Jessica

Oh, Juntaek

Sze, Kong-Hung

Zhang, Anna Jinxia https://orcid.org/0000-0002-5087-3614
Chu, Hin

Kok, Kin-Hang https://orcid.org/0000-0003-3426-332X
Wang, Dong https://orcid.org/0000-0002-2829-1546
Cai, Xue-Hui

Esko, Jeffrey D.

Hung, Ivan Fan-Ngai

Li, Ronald Adolphus

Chen, Honglin https://orcid.org/0000-0001-5108-8338
Sun, Hongzhe https://orcid.org/0000-0001-6697-6899
Jin, Dong-Yan https://orcid.org/0000-0002-2778-3530
Sun, Ren

Chanda, Sumit K. https://orcid.org/0000-0001-9399-7927
Yuen, Kwok-Yung https://orcid.org/0000-0002-2083-1552
License Information

Text and Data Mining valid from 2021-03-16

Version of Record valid from 2021-03-16
More Information

Article History

Received: 30 September 2020

Accepted: 8 March 2021

First Online: 16 March 2021

Competing interests

: J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. S.K.C. is an inventor on a patent application on repurposed antiviral compounds for SARS-CoV-2 owned by Scripps Research and Sanford Burnham Prebys. US Patent Application Serial No. 63/010630, entitled ‘Methods and Compositions for Antiviral Treatment’ relates to aspects of this work and was filed on 15 April 2020. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The other authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below